Identification of new aminoacid amides containing the imidazo[2,1-b] benzothiazol-2-ylphenyl moiety as inhibitors of tumorigenesis by oncogenic Met signaling

European Journal of Medicinal Chemistry

Volumn 47, Issue 1, 2012, Pages 239-254

  Furlan, Alessandro ^a   Colombo, Francesco ^b   Kover, Andrea ^c   Issaly, Nathalie ^a   Tintori, Cristina ^d   Angeli, Lucilla ^d   Leroux, Vincent ^e,f   Letard, Sébastien ^g   Amat, Mercedes ^c   Asses, Yasmine ^e   Maigret, Bernard ^e   Dubreuil, Patrice ^g   Botta, Maurizio ^d   Dono, Rosanna ^a   Bosch, Joan ^c   Piccolo, Oreste ^h   Passarella, Daniele ^b   Maina, Flavio ^a  

^a AIX MARSEILLE UNIVERSITÉ   (France)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF BARCELONA   (Spain)

^d UNIVERSITY OF SIENA   (Italy)

^e UNIVERSITÉ DE LORRAINE   (France)

^f UNIVERSITY OF OSLO   (Norway)

^g INSERM   (France)

^h Studio di Consulenza Scientifica   (Italy)

Author keywords

Aminoacid amide derivatives; Anti tumor agents; Imidazo 2,1 b benzothiazol 2 ylphenyl moiety; Inhibitor binding modes; Met RTK; Met signaling inhibitor

Indexed keywords

AMINO ACID DERIVATIVE; N [4 (IMIDAZO[2,1 B]BENZOTHIAZOL 2 YL)PHENYL] 2 [2 (3,5 BIS(TRIFLUOROMETHYL)PHENYL) ACETAMIDO] 3 PHENYLPROPANAMIDE; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CELL SURVIVAL; CONTROLLED STUDY; DRUG DESIGN; DRUG DETERMINATION; DRUG IDENTIFICATION; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERANCE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; MOLECULAR DOCKING; MOUSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE;

AMIDES; AMINO ACIDS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOGS; DRUG DESIGN; ENZYME ACTIVATION; HUMANS; IMIDAZOLES; MODELS, MOLECULAR; PROTEIN CONFORMATION; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION; USER-COMPUTER INTERFACE;

EID: 84855788011     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2011.10.051     Document Type: Article

References (50)

1. E. Zwick, J. Bange, and A. Ullrich Receptor tyrosine kinases as targets for anticancer drugs Trends Mol. Med. 8 2002 17 23
2. M.A. Lemmon, and J. Schlessinger Cell signaling by receptor tyrosine kinases Cell 141 2010 1117 1134
3. T. Hunter Tyrosine phosphorylation: thirty years and counting Curr. Opin. Cell Biol. 21 2009 140 146
4. B.S. Knudsen, and G. Vande Woude Showering c-MET-dependent cancers with drugs Curr. Opin. Genet. Dev. 18 2008 87 96
5. P. Kaposi-Novak, J.S. Lee, L. Gomez-Quiroz, C. Coulouarn, V.M. Factor, and S.S. Thorgeirsson Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype J. Clin. Invest. 116 2006 1582 1595
6. L. Trusolino, A. Bertotti, and P.M. Comoglio MET signalling: principles and functions in development, organ regeneration and cancer Nat. Rev. Mol. Cell Biol. 11 2010 834 848
7. F. Maina, F. Casagranda, E. Audero, A. Simeone, P. Comoglio, R. Klein, and C. Ponzetto Uncoupling of Grb2 from the Met receptor in vivo reveals complex roles in muscle development Cell 87 1996 531 542
8. F. Maina, M.C. Hilton, R. Andres, S. Wyatt, R. Klein, and A.M. Davies Multiple roles for hepatocyte growth factor in sympathetic neuron development Neuron 20 1998 835 846
9. F. Maina, M.C. Hilton, C. Ponzetto, A.M. Davies, and R. Klein Met receptor signaling is required for sensory nerve development and HGF promotes axonal growth and survival of sensory neurons Genes Dev. 11 1997 3341 3350
10. F. Maina, G. Pante, F. Helmbacher, R. Andres, A. Porthin, A.M. Davies, C. Ponzetto, and R. Klein Coupling Met to specific pathways results in distinct developmental outcomes Mol. Cell 7 2001 1293 1306
11. A. Moumen, A. Ieraci, S. Patane, C. Sole, J.X. Comella, R. Dono, and F. Maina Met signals hepatocyte survival by preventing Fas-triggered FLIP degradation in a PI3k-Akt-dependent manner Hepatology 45 2007 1210 1217
12. A. Moumen, S. Patane, A. Porras, R. Dono, and F. Maina Met acts on Mdm2 via mTOR to signal cell survival during development Development 134 2007 1443 1451
13. M. Genestine, E. Caricati, A. Fico, S. Richelme, H. Hassani, C. Sunyach, F. Lamballe, G.C. Panzica, B. Pettmann, F. Helmbacher, C. Raoul, F. Maina, and R. Dono Enhanced neuronal Met signalling levels in ALS mice delay disease onset Cell Death Dis. 2 2011 e130
14. L. Tonges, T. Ostendorf, F. Lamballe, M. Genestine, R. Dono, J.C. Koch, M. Bahr, F. Maina, and P. Lingor Hepatocyte growth factor protects retinal ganglion cells by increasing neuronal survival and axonal regeneration in vitro and in vivo J. Neurochem. 117 2011 892 903
15. A. Furlan, V. Stagni, A. Hussain, S. Richelme, F. Conti, A. Prodosmo, A. Destro, M. Roncalli, D. Barila, and F. Maina Abl interconnects oncogenic Met and p53 core pathways in cancer cells Cell Death Differ. 18 2011 1608 1616
16. C.L. Arteaga HER3 and mutant EGFR meet MET Nat. Med. 13 2007 675 677
17. J.M. Stommel, A.C. Kimmelman, H. Ying, R. Nabioullin, A.H. Ponugoti, R. Wiedemeyer, A.H. Stegh, J.E. Bradner, K.L. Ligon, C. Brennan, L. Chin, and R.A. DePinho Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies Science 318 2007 287 290
18. J.A. Engelman, K. Zejnullahu, T. Mitsudomi, Y. Song, C. Hyland, J.O. Park, N. Lindeman, C.M. Gale, X. Zhao, J. Christensen, T. Kosaka, A.J. Holmes, A.M. Rogers, F. Cappuzzo, T. Mok, C. Lee, B.E. Johnson, L.C. Cantley, and P.A. Janne MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling Science 316 2007 1039 1043
19. D.L. Shattuck, J.K. Miller, K.L. Carraway 3rd, and C. Sweeney Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells Cancer Res. 68 2008 1471 1477
20. P.M. Comoglio, S. Giordano, and L. Trusolino Drug development of MET inhibitors: targeting oncogene addiction and expedience Nat. Rev. Drug Discov. 7 2008 504 516
21. T.L. Underiner, T. Herbertz, and S.J. Miknyoczki Discovery of small molecule c-Met inhibitors: evolution and profiles of clinical candidates Anticancer Agents Med. Chem. 10 2010 7 27
22. J.J. Cui Inhibitors targeting hepatocyte growth factor receptor and their potential therapeutic applications Expert Opin. Ther. Patents 17 2007 1035 1045
23. H.M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T.N. Bhat, H. Weissig, I.N. Shindyalov, and P.E. Bourne The protein data bank Nucleic Acids Res. 28 2000 235 242
24. R. Capdeville, E. Buchdunger, J. Zimmermann, and A. Matter Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug Nat. Rev. Drug Discov. 1 2002 493 502
25. T. Schindler, W. Bornmann, P. Pellicena, W.T. Miller, B. Clarkson, and J. Kuriyan Structural mechanism for STI-571 inhibition of abelson tyrosine kinase Science 289 2000 1938 1942
26. Y. Liu, and N.S. Gray Rational design of inhibitors that bind to inactive kinase conformations Nat. Chem. Biol. 2 2006 358 364
27. M.D. Jacobs, P.R. Caron, and B.J. Hare Classifying protein kinase structures guides use of ligand-selectivity profiles to predict inactive conformations: structure of lck/imatinib complex Proteins 70 2008 1451 1460
28. Y. Asses, V. Leroux, S. Tairi-Kellou, R. Dono, F. Maina, and B. Maigret Analysis of c-Met kinase domain complexes: a new specific catalytic site receptor model for defining binding modes of ATP-competitive ligands Chem. Biol. Drug Des 74 2009 560 570
29. I. Dussault, and S.F. Bellon c-Met inhibitors with different binding modes: two is better than one Cell Cycle 7 2008 1157 1160
30. N. Schiering, S. Knapp, M. Marconi, M.M. Flocco, J. Cui, R. Perego, L. Rusconi, and C. Cristiani Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a Proc. Natl. Acad. Sci. U S A 100 2003 12654 12659
31. S.F. Bellon, P. Kaplan-Lefko, Y. Yang, Y. Zhang, J. Moriguchi, K. Rex, C.W. Johnson, P.E. Rose, A.M. Long, A.B. O'Connor, Y. Gu, A. Coxon, T.S. Kim, A. Tasker, T.L. Burgess, and I. Dussault c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations J. Biol. Chem. 283 2008 2675 2683
32. S. Patane, N. Pietrancosta, H. Hassani, V. Leroux, B. Maigret, J.L. Kraus, R. Dono, and F. Maina A new Met inhibitory-scaffold identified by a focused forward chemical biological screen Biochem. Biophys. Res. Commun. 375 2008 184 189
33. Z.W. Cai, D. Wei, G.M. Schroeder, L.A. Cornelius, K. Kim, X.T. Chen, R.J. Schmidt, D.K. Williams, J.S. Tokarski, Y. An, J.S. Sack, V. Manne, A. Kamath, Y. Zhang, P. Marathe, J.T. Hunt, L.J. Lombardo, J. Fargnoli, and R.M. Borzilleri Discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitors Bioorg. Med. Chem. Lett. 18 2008 3224 3229
34. N.D. D'Angelo, S.F. Bellon, S.K. Booker, Y. Cheng, A. Coxon, C. Dominguez, I. Fellows, D. Hoffman, R. Hungate, P. Kaplan-Lefko, M.R. Lee, C. Li, L. Liu, E. Rainbeau, P.J. Reider, K. Rex, A. Siegmund, Y. Sun, A.S. Tasker, N. Xi, S. Xu, Y. Yang, Y. Zhang, T.L. Burgess, I. Dussault, and T.S. Kim Design, synthesis, and biological evaluation of potent c-Met inhibitors J. Med. Chem. 51 2008 5766 5779
35. M. Amat, A. Kövér, D. Jokic, O. Lozano, M. Pérez, N. Landoni, F. Subrizi, J. Bautista, and J. Bosch Synthesis of a tetrahydroimidazo[2′,1′:2,3]thiazolo[5,4-c]pyridine derivative with Met inhibitory activity ARKIVOC 3 2010 145 151
36. G.K. Chan, B.A. Lutterbach, B.S. Pan, I. Kariv, and A.A. Szewczak High-throughput analysis of HGF-stimulated cell scattering J. Biomol. Screen. 13 2008 847 854
37. M. Sattler, Y.B. Pride, P. Ma, J.L. Gramlich, S.C. Chu, L.A. Quinnan, S. Shirazian, C. Liang, K. Podar, J.G. Christensen, and R. Salgia A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase Cancer Res. 63 2003 5462 5469
38. H.Y. Zou, Q. Li, J.H. Lee, M.E. Arango, S.R. McDonnell, S. Yamazaki, T.B. Koudriakova, G. Alton, J.J. Cui, P.P. Kung, M.D. Nambu, G. Los, S.L. Bender, B. Mroczkowski, and J.G. Christensen An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms Cancer Res. 67 2007 4408 4417
39. K.M. Nicholson, C.H. Streuli, and N.G. Anderson Autocrine signalling through erbB receptors promotes constitutive activation of protein kinase B/Akt in breast cancer cell lines Breast Cancer Res. Treat. 81 2003 117 128
40. S.Y. Wang, B. Chen, Y.Q. Zhan, W.X. Xu, C.Y. Li, R.F. Yang, H. Zheng, P.B. Yue, S.H. Larsen, H.B. Sun, and X. Yang SU5416 is a potent inhibitor of hepatocyte growth factor receptor (c-Met) and blocks HGF-induced invasiveness of human HepG2 hepatoma cells J. Hepatol. 41 2004 267 273
41. F. Qian, S. Engst, K. Yamaguchi, P. Yu, K.A. Won, L. Mock, T. Lou, J. Tan, C. Li, D. Tam, J. Lougheed, F.M. Yakes, F. Bentzien, W. Xu, T. Zaks, R. Wooster, J. Greshock, and A.H. Joly Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases Cancer Res. 69 2009 8009 8016
42. N. Munshi, S. Jeay, Y. Li, C.R. Chen, D.S. France, M.A. Ashwell, J. Hill, M.M. Moussa, D.S. Leggett, and C.J. Li ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity Mol. Cancer Ther. 9 2010 1544 1553
43. G. Jones, P. Willett, and R.C. Glen Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation J. Mol. Biol. 245 1995 43 53
44. G. Jones, P. Willett, R.C. Glen, A.R. Leach, and R. Taylor Development and validation of a genetic algorithm for flexible docking J. Mol. Biol. 267 1997 727 748
45. M.L. Verdonk, J.C. Cole, M.J. Hartshorn, C.W. Murray, and R.D. Taylor Improved protein-ligand docking using GOLD Proteins 52 2003 609 623
46. W.L. Jorgensen, D.S. Maxwell, and J. Tirado-Rives Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids J. Am. Chem. Soc. 118 1996 11225 11236
47. N. Pietrancosta, F. Maina, R. Dono, A. Moumen, C. Garino, Y. Laras, S. Burlet, G. Quelever, and J.L. Kraus Novel cyclized Pifithrin-alpha p53 inactivators: synthesis and biological studies Bioorg. Med. Chem. Lett. 15 2005 1561 1564
48. Q. Chao, K.G. Sprankle, R.M. Grotzfeld, A.G. Lai, T.A. Carter, A.M. Velasco, R.N. Gunawardane, M.D. Cramer, M.F. Gardner, J. James, P.P. Zarrinkar, H.K. Patel, and S.S. Bhagwat Identification of N-(5-tert-butyl-isoxazol-3-yl)- N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2, 1-b][1,3]benzothiazol-2-yl] phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor J. Med. Chem. 52 2009 7808 7816
49. J. Segarra, L. Balenci, T. Drenth, F. Maina, and F. Lamballe Combined signaling through ERK, PI3K/AKT, and RAC1/p38 is required for Met-triggered cortical neuron migration J. Biol. Chem. 281 2006 4771 4778
50. F. Lamballe, M. Genestine, N. Caruso, V. Arce, S. Richelme, F. Helmbacher, and F. Maina Pool-specific regulation of motor neuron survival by neurotrophic support J Neurosci. 31 2011 11144 11158